A Phase 2 interventional study of LB54640 in POMC Deficiency Obesity, PCSK1 Deficiency Obesity and LEPR Deficiency Obesity, sponsored by LG Chem. Not yet recruiting at 2 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-11-02.
Sponsored by LG Chem · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 475 studies in Obesity with a site in France — 111 open to participants now, 127 under way, 25 of them phase 3. Obesity · France.
Among the 475 studies in Obesity with a site in France, this one is the 352nd largest by planned enrollment of the 354 interventional ones that give a count, is one of 25 that started in 2023, is one of 16 in phase 2, reaches primary completion later than 7 of the 126 other live ones, and was the 381st registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →111 of the 475 studies in Obesity with a site in France are open now. Recruiting first, the newest first:
Laboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et Pathologiques · Sites in France
Ages 50–75
AstraZeneca · Sites in France, United States, Argentina and 13 more countries
Ages 18+
Novo Nordisk A/S · Sites in France, United States, Belgium and 7 more countries
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 18–75
Universite du Littoral Cote d'Opale · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
475 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 21 · Phase 3 61 · Phase 4 14
First in 2001; this study’s year is marked. 25 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 4 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 80 across the 354 interventional studies, 133 across the 121 observational. Of the 295 that completed or were terminated, 16 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 475 have an industry lead sponsor. The 10 most frequent:
LG Chem is the lead sponsor of 71 studies on the registry; 8 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 1 (8%) have results posted.
LG Chem has 2 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
30 of the studies in Obesity with a site in France that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT03516968Phase 3Hospices Civils de LyonMonthly Boluses Versus Daily Doses for Correcting Blood Vitamin D Deficit in Obese Children and Adolescents | 2027-03 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
Add all 30 to your calendar (.ics) → With an account.
Among the 475 studies in Obesity with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study was to assess the efficacy of LB54640 in participants with rare genetic disorders of obesity
Patients with obesity due to POMC, PCSK1 or LEPR deficiency will be enrolled to receive LB54640 by oral administration for 16 weeks. After 16 weeks of treatment, the participant may enter a long term extension phase and receive treatment for up to 1 year.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LB54640 once daily by oral administration
Drug: LB54640
LB54640 QD Oral
Change of BMI
Time frame: From baseline to Week 16
Frequency and severity of adverse events (AE)
Time frame: From first dose up to Week 52
Frequency and severity of adverse events of special interest (AESI)
Time frame: From first dose up to Week 52
Mean change and mean percentage change from baseline in body weight
Time frame: From baseline up to Week 52
Mean change and mean percentage change from baseline in waist circumference.
Time frame: From baseline up to Week 52
Mean change and mean percentage change from baseline in Hunger Questionnaire Scores
The question will asked using the Hunger Questionnaire. The questionnaire consists of a new 5-item, patient-reported scale assessing major eating-related factors (worst and average hunger, appetite, craving, and satiety).
Time frame: From baseline up to Week 52
Mean change and mean percentage change from baseline in body composition assessed by dual energy x-ray absorptiometry
Fat mass and lean mass will be measured through dual energy x-ray absorptiometry
Time frame: From baseline up to Week 52
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2023; primary completion for Dec 2024, 12 months later.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 12 months is close to that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bivamelagon